N@N

C, HIG, ABT, BSX, SU, CVS With Highest Daily Short Volume On NYSE Monday

^{Published on 2009-09-28 14:35:34, Last Modified on 2010-12-22 14:48:51 - WOPRAI}
 

September 29, 2009 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net, has reviewed the NYSE Daily Short Volume Report for Monday, September 28th, 2009 and come to the following statistical conclusions. There were 6,423 stocks with daily short volume reported and total NYSE trading volume of 911,381,327 shares. Total Daily Short Volume was 430,902,515 shares. 47.28% of all trading on the NYSE Monday was short selling. The chart below highlights 6 stocks that had the highest daily short volume on Monday. Citigroup (NYSE: C), Hartford Financial Services (NYSE: HIG), Abbott Laboratories (NYSE: ABT), Boston Scientific (NYSE: BSX), Suncor Energy (NYSE: SU) and CVS Caremark (NYSE: CVS). To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.buyins.net.

Date Symbol Short Volume Total Volume Market Percent

20090928 C 16,226,092 26,598,298 P 61.00%

20090928 HIG 1,661,265 3,154,020 P 52.67%

20090928 ABT 1,221,824 2,769,325 P 44.12%

20090928 BSX 1,108,353 2,455,962 P 45.13%

20090928 SU 894,389 1,222,104 P 73.18%

20090928 CVS 810,720 1,855,303 P 43.70%

In late October 2008 the SEC updated Regulation SHO requiring that all short sellers must locate, borrow and deliver any shares they have shorted, no exceptions, by T+3 settlement date. If not, a buy-in must be forced by the broker dealer that the short seller transacted through by the opening of the market on T+4. Since a company first appears on the naked short list when short sellers have been failing to deliver for 5 consecutive trading days, stocks should theoretically never be on the naked short list again. BUYINS.NET will monitor the exchangesa� naked short lists daily and issue an alert and notify the SEC and FINRA should short sellers fail to deliver on any short sales.

Reg SHO Rule 204 (i) requires brokers to deliver shares on long and short sales of publicly traded equity securities by settlement date, (ii) continues to require brokers to close-out fails to deliver by the beginning of trading on T+4 for short sales and T+6 for long sales, (iii) precludes clearing brokers and their introducing brokers from selling short a security, other than on a pre-borrowed basis, if a fail to deliver in that security is not timely closed out until the fail is closed out and that close-out transaction settles, (iv) allows clearing brokers to allocate fails to introducing brokers and (v) continues to permit brokers to rely upon pre-fail credit to satisfy Rule 204's close-out requirement to avoid the pre-borrow requirements when a fail at a clearing broker has not been closed out. However, the SEC liberalized certain of these provisions in several regards. For example, permanent Rule 204 now allows a broker to close-out a fail on a long sale by borrowing the security, whereas Rule 204T had only permitted closing out long fails by buying-in, which should alleviate some of the buy-in risk for investors that experience long fails. Similar relief was extended to close-outs for market maker fails, so that a fail from a bona fide market making transaction (including short and long fails) can now be closed out by the beginning of trading on T+6 by borrowing the security. Further, Rule 204 now permits a broker to borrow securities to obtain pre-fail credit for early close-outs, whereas temporary Rule 204T only permitted pre-fail credit to be obtained by purchases of securities.

The SEC refused requests to extend the close-out deadline for fails to deliver to the close of business on the close-out deadline, choosing instead to retain the requirement that all fails be closed out by the beginning of trading on the applicable close-out deadline. The Commission also rejected requests for a fail to deliver exception that would have provided an exception from the close-out requirements if a clearing broker's fail position was below a certain amount but said that it would continue to monitor whether a de minimis or odd lot exception could be warranted.

Citigroup Inc. (NYSE: C), a global financial services company, provides consumers, corporations, governments, and institutions with a range of financial products and services, including consumer banking and credit, corporate and investment banking, securities brokerage, and wealth management. The company has two primary segments, Citicorp and Citi Holdings. The Citicorp segment operates as a global bank for businesses and consumers with two primary businesses, Institutional Clients Group and Regional Consumer Banks. The Institutional Clients Group business provides transaction services, such as treasury and trade solutions, and securities and fund services; and securities and banking services, including market making, underwriting and advisory, corporate lending, private banking, and institutional asset management. It serves corporate, institutional, public sector, and private banking clients. The Regional Consumer Banks business provides traditional banking services, including retail banking, and branded cards, and small and middle market commercial banking in North America, Asia, Latin America, and Europe, Middle East, and Africa. The Citi Holdings segment has three businesses: Brokerage and Asset Management, Local Consumer Finance, and Special Asset Pool. Brokerage and Asset Management business includes the 49% stake in Morgan Stanley Smith Barney, Nikko Cordial Securities, Nikko Asset Management, and Select Global Asset Management (Retail Alternative Investments) operations. Local Consumer Finance consists of CitiFinancial, Mortgage, Student Loans, Auto Loans, Retail Partner Cards, Primerica, and CRE activities in North America, as well as the International Consumer Finance activates. Special Asset Pool business includes key S&B risk exposures and other covered assets. Citigroup Inc. has approximately 200 million customer accounts and operates in approximately 140 countries. The company was founded in 1812 and is based in New York, New York.

The Hartford Financial Services Group, Inc. (NYSE: HIG), through its subsidiaries, provides insurance and financial services in the United States and internationally. It engages in life, and property and casualty insurance businesses. The life insurance business comprises six segments: Retail Products Group (Retail), Retirement Plans, International and Institutional Solutions Group (Institutional), Individual Life, Group Benefits, and International. Retail segment offers variable and fixed market value adjusted annuities, retail mutual funds, 529 college savings plans, and Canadian and offshore investment products. Retirement Plans segment provides products and services to corporations and municipalities. Institutional segment offers institutional liability products and variable private placement life insurance, as well as mutual funds to institutional investors. Individual Life segment sells variable universal, whole, and term life products. Group Benefits segment offers group life, accident, and disability coverage. International segment provides investments, retirement savings, and other insurance and savings products in Japan, Brazil, Ireland, and the United Kingdom. The property and casualty insurance business includes five segments: Personal Lines, Small Commercial, Middle Market, Specialty Commercial, and Other Operations. Personal Lines segment offers automobile, homeownersa�, and home-based business coverage. Small Commercial segment provides standard commercial insurance coverage to small commercial businesses. Other Operations segment comprises certain property and casualty insurance operations, including the companya�s asbestos and environmental exposures. The company was formerly known as ITT-Hartford Group, Inc. and changed its name in 1972. The Hartford Financial Services Group, Inc. was founded in 1810 and is headquartered in Hartford, Connecticut.

Abbott Laboratories (NYSE: ABT) manufactures and sells health care products worldwide. The companya�s Pharmaceutical Products segment offers adult and pediatric pharmaceuticals for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, psoriasis, Crohn's disease, dyslipidemia, HIV infection, hypothyroidism, advanced prostate cancer, endometriosis and central precocious puberty, anemia caused by uterine fibroids, obesity, epilepsy and bipolar disorder, migraines, and secondary hyperparathyroidism; and provides anesthesia products and anti-infectives. Its Diagnostic Products segment offers immunoassay systems; chemistry systems; assays used for screening and/or diagnosis for drugs of abuse, cancer, therapeutic drug monitoring, fertility, physiological diseases, and infectious diseases; instruments that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infections agents; genomic-based tests; hematology systems and reagents; and point-of-care diagnostic systems and tests for blood analysis. The companya�s Nutritional Products segment provides various forms of prepared infant formula and follow-on formula, adult and other pediatric nutritional products, nutritional products used in enteral feeding in health care institutions, and bars and nutritional brands. Its Vascular Products segment offers coronary, endovascular, and vessel closure devices, such as drug-eluting coronary stent systems, coronary metallic stents, balloon dilatation products, coronary guidewires, vessel closure devices, and carotid stent systems to treat vascular disease. Abbott serves wholesalers, government agencies, health care facilities, specialty pharmacies, independent retailers, hospitals, clinics, physicians' offices, blood banks, commercial laboratories, alternate-care testing sites, plasma protein therapeutic companies, and third-party distributors. The company was founded in 1888 and is based in Abbott Park, Illinois.

Boston Scientific Corporation (NYSE: BSX) operates as a developer, manufacturer, and marketer of medical devices used in various interventional medical specialties worldwide. Its products help physicians and other medical professionals improve the patientsa� quality of life by providing alternatives to surgery. The companya�s cardiovascular group consists of drug-eluting and bare-metal stents, coronary revascularization products, Intraluminal ultrasound imaging catheters and systems, Embolic protection system, peripheral and neurovascular interventions, electrophysiology devices, and cardiac rhythm management devices. This groupa�s products are used to treat cardiovascular, peripheral vascular and neurovascular diseases, cardiac arrhythmias, and neuro and aortic aneurysms. Its endosurgery group includes esophageal, gastric, and duodenal intervention products; colorectal, pancreatico-biliary, and pulmonary intervention devices; and products for urinary tract intervention and bladder disease, prostate intervention, pelvic floor reconstruction and urinary incontinence, and gynecology. This groupa�s products are used for the treatment of gastrointestinal diseases, esophagitis, portal hypertension, peptic ulcers, esophageal cancer, polyps, inflammatory bowel disease, diverticulitis, colon cancer, and benign prostatic hyperplasia. The companya�s neuromodulation group comprises Precision Spinal Cord Stimulation system for the treatment of chronic pain of the lower back and legs. Its cardiac rhythm management group offers implantable devices used to treat cardiac arrhythmias and heart failure. Boston Scientific Corporation markets its products through direct sales force, and a network of distributors and dealers. The company was founded in 1979 and is headquartered in Natick, Massachusetts with additional offices in Tokyo, Japan and Paris, France.

Suncor Energy, Inc. (NYSE: SU), together with its subsidiaries, operates as an integrated energy company in Canada. It operates through four segments: Oil Sands, Natural Gas, Energy Marketing and Refining, and Refining and Marketing. The Oil Sands segment recovers bitumen, primarily through oil sands mining and in-situ development, and upgrades it into refinery feedstock, diesel fuel, and by-products. This segment offers light sweet crude oil/diesel and light sour crude oil/bitumen. The Natural Gas segment explores, acquires, develops, and produces natural gas and natural gas liquids from reserves in western Alberta and northeastern British Columbia. This segment also acquires land and explores for coal bed methane in the United States. The Energy Marketing and Refining segment refines crude oil into a range of petroleum, petrochemical, and biofuel products. It offers gasoline, diesel, jet fuels, petrochemicals, heating fuels, and heavy fuel oils for industrial, wholesale, commercial, and retail customers principally in Ontario and Quebec. This segment also engages in third party energy marketing and trading activities. The Refining and Marketing segment refines and markets jet fuels, diesel, gasoline, and asphalt. This segment also transports crude oil through wholly or partly owned pipelines in Wyoming and Colorado. In addition, the company carry on energy trading activities focused principally on buying and selling futures contracts and other derivative instruments based on the commodities it produce. Suncor Energy sells its products in the United States, Canada, and Europe. The company, formerly known as Suncor, Inc., was founded in 1953 and is headquartered in Calgary, Canada.

CVS Caremark Corporation (NYSE: CVS), a pharmacy services company, provides prescriptions and related healthcare services in the United States. The company operates through two segments, Pharmacy Services and Retail Pharmacy. The Pharmacy Service segment provides a range of prescription benefit management services, including mail order pharmacy services, specialty pharmacy services, plan design and administration, formulary management, and claims processing. This segment serves primarily employers, insurance companies, unions, government employee groups, managed care organizations and other sponsors of health benefit plans, and individuals. As of December 31, 2008, the Pharmacy Services segment operated 58 retail specialty pharmacy stores, 19 specialty mail order pharmacies, and 7 mail service pharmacies located in 26 states of the United States, Puerto Rico, and the District of Columbia. The Retail Pharmacy Segment sells prescription drugs, over-the-counter drugs, beauty products and cosmetics, photo finishing, seasonal merchandise, greeting cards, and convenience foods through its pharmacy retail stores, and online. This segment also provides health care services. As of December 31, 2008, this segment operated 6,923 retail drugstores located in 41 states and the District of Columbia; and 560 retail health care clinics in 27 states. The company was founded in 1892 and is headquartered in Woonsocket, Rhode Island.

About BUYINS.NET

WWW.BUYINS.NET is a service designed to help bonafide shareholders of publicly traded US companies fight naked short selling. Naked short selling is the illegal act of short selling a stock when no affirmative determination has been made to locate shares of the stock to hypothecate in connection with the short sale. Buyins.net has built a proprietary database that uses Threshold list feeds from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the naked short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted and naked shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short and naked short trades.

BUYINS.NET has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2,650,000,000 short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like Buyins.net to access the data.

The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha�s short transactions, BUYINS.NET provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.

All material herein was prepared by BUYINS.NET, based upon information believed to be reliable. The information contained herein is not guaranteed by BUYINS.NET to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. Occassionally companies or third parties pay $995 per month to purchase data for information provided in monthly reports. The data service can be cancelled at any time. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. BUYINS.NET is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. BUYINS.NET will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

BUYINS.NET and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of BUYINS.NET, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor. By visiting BUYINS.NET or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. BUYINS.NET, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to BUYINS.NET and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State. Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. BUYINS.NET does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. BUYINS.NET places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.

Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BUYINS.NET undertakes no obligation to update such statements.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.

Contact: Thomas Ronk, CEO www.BUYINS.net +1-800-715-9999 Tom@buyins.net